Skip to main content
. 2021 Mar 30;13(4):581. doi: 10.3390/v13040581

Figure 3.

Figure 3

Response to repeat dosing of chimpanzees with HBV siRNAs. HBeAg-positive and HBeAg-negative chimpanzees began daily NUC treatment for a lead-in period of 8 to 24 weeks prior to commencing Q4W dosing with ARC-520, beginning on Day 1. HBsAg reduction is shown relative to Day 1 of ARC-520 treatment. (a) HBsAg reduction following 6 doses of ARC-520 in HBeAg-positive and HBeAg-negative chimpanzees. (b) Four HBeAg-negative chimpanzees received 7 doses of ARC-520. Then, two chimpanzees received three additional doses of ARC-520 while two animals received three doses of siHBV-75 + EX1. Reproduced from [1]. Reprinted with permission from AAAS.